IP Library › Granted Patent US 12661361
Granted Patent B2
US 12661361 · App. 19/386,839 · Granted Jun 23, 2026

Resmetirom for reducing liver volume

Inventor: Rebecca Taub (Villanova, PA)
Assignee: Madrigal Pharmaceuticals, Inc.
A61K31/53A61P1/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12661361
App. No.
19/386,839
Filed
Nov 12, 2025
Granted
Jun 23, 2026
Kind
B2
Art Unit
1611
USPC
514/242
Abstract

The present disclosure describes a method of reducing liver volume in a cirrhotic or non-cirrhotic subject, the method comprising administering resmetirom, a prodrug thereof, or a pharmaceutically acceptable salt of the resmetirom or the resmetirom prodrug. The present disclosure also describes a method of treating NASH in a cirrhotic subject in need thereof, the method comprising administering to the subject resmetirom, a prodrug thereof, or a pharmaceutically acceptable salt of the resmetirom or the resmetirom prodrug.

Claims (10)

1 . A method of treating well-compensated cirrhotic nonalcoholic steatohepatitis (NASH) comprising administering to a human subject in need thereof a therapeutically effective amount of resmetirom or a pharmaceutically acceptable salt thereof.

2 . The method of claim 1 , wherein the therapeutically effective amount of resmetirom or the pharmaceutically acceptable salt thereof is 60 mg to 80 mg.

3 . The method of claim 1 , wherein the therapeutically effective amount of resmetirom or the pharmaceutically acceptable salt thereof is 60 mg.

4 . The method of claim 1 , wherein the therapeutically effective amount of resmetirom or the pharmaceutically acceptable salt thereof is 80 mg.

5 . The method of claim 1 , wherein the therapeutically effective amount of resmetirom or the pharmaceutically acceptable salt thereof is 100 mg.

6 . A method of reducing liver volume comprising administering to a human subject in need thereof a therapeutically effective amount of resmetirom or a pharmaceutically acceptable salt thereof, wherein the human subject in need thereof has well-compensated cirrhotic nonalcoholic steatohepatitis (NASH).

7 . The method of claim 6 , wherein the therapeutically effective amount of resmetirom or the pharmaceutically acceptable salt thereof is 60 mg to 80 mg.

8 . The method of claim 6 , wherein the therapeutically effective amount of resmetirom or the pharmaceutically acceptable salt thereof is 60 mg.

9 . The method of claim 6 , wherein the therapeutically effective amount of resmetirom or the pharmaceutically acceptable salt thereof is 80 mg.

10 . The method of claim 6 , wherein the therapeutically effective amount of resmetirom or the pharmaceutically acceptable salt thereof is 100 mg.